Discontinued — last reported Q4 '25
Elevance Health Acquisitions increased by 84.8% to -$5.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 25.0%, from -$4.00M to -$5.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -60.1% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.42B | $0.00 | $34.00M | $61.00M | $548.00M | $14.00M | $26.00M | $1.64B | $13.00M | -$81.00M | $0.00 | $1.12B | $4.00M | $0.00 | $3.69B | -$4.00M | -$50.00M | -$1.00M | -$33.00M | -$5.00M |
| QoQ Change | — | -100.0% | — | +79.4% | +798.4% | -97.4% | +85.7% | >999% | -99.2% | -723.1% | +100.0% | — | -99.6% | -100.0% | — | -100.1% | <-999% | +98.0% | <-999% | +84.8% |
| YoY Change | — | — | — | — | -84.0% | — | -23.5% | >999% | -97.6% | -678.6% | -100.0% | -31.6% | -69.2% | +100.0% | — | -100.4% | <-999% | — | -100.9% | -25.0% |